Printed From:

QUESTIONS ABOUT NOVEL CORONAVIRUS?
CLICK HERE.

DUPIXENT specifically targets the IL-4α receptor in severe asthma1–3

  • The interleukins; IL-4 and IL-13, are important in the development of Type 2 inflammation and its downstream effects in severe asthma2–7
  • DUPIXENT is a fully human monoclonal antibody for administration by subcutaneous injecton1

Learn more about how
DUPIXENT works


Watch video

DUPIXENT inhibits IL-4 and IL-13 signalling1,2

DUPIXENT:

  • Binds specifically to the IL-4Rα subunit shared by the receptor complexes for IL-4 and IL-131–4
  • Selectively inhibits the signalling of IL-4 via the Type 1 and 2 receptors for IL-41–4
  • Selectively inhibits IL-13 signalling via the Type 2 receptor for IL-131–4

DUPIXENT inhibits IL-4 and IL-13 signalling1,2

DUPIXENT:

  • Binds specifically to the IL-4Rα subunit shared by the receptor complexes for IL-4 and IL-131–4
  • Selectively inhibits the signalling of IL-4 via the Type 1 and 2 receptors for IL-41–4
  • Selectively inhibits IL-13 signalling via the Type 2 receptor for IL-131–4

Inhibition of IL-4 and IL-13 markedly decreases:1,2

Total and
allergen-specific IgE

Eosinophilic
lung inflammation

Fractional exhaled nitric oxide (FeNO), a marker
of IL-13 related to lung inflammation

INTRODUCING THE DUPIXENT PRE-FILLED PEN

A convenient option to ensure patients
administer DUPIXENT as directed1

FeNO, fractional exhaled nitric oxide; IgE, Immunoglobulin E; IL, interleukin; R, receptor; γC, gamma C subunit.

References

  1. Sanofi Genzyme. Dupixent Summary of Product Characteristics, December 2020.
  2. Gandhi NA, et al. Nat Rev Drug Discov. 2016;15:35–50.
  3. Krings JG, et al. J Allergy Clin Immunol Pract. 2019;7(5):1379–1392.
  4. Doran E, et al. Front Med. 2017;4:139.
  5. Tran TN, et al. Ann Allergy Asthma Immunol. 2016;116(1):37–42.
  6. Seys SF, et al. Respir Res. 2017;18:39.
  7. Peters MC, et al. J Allergy Clin Immunol. 2014;133(2):388–394.